What Affinia Therapeutics does

Affinia Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in Waltham, Massachusetts, that develops rationally designed adeno-associated virus (AAV) gene therapies for rare and prevalent genetic diseases. Its lead program, AFTX-201, is an investigational gene therapy delivering a full-length human BAG3 transgene via the proprietary ATC-187 capsid for the treatment of BAG3-associated dilated cardiomyopathy (BAG3 DCM), a genetic heart condition affecting more than 70,000 patients across the U.S., Canada, the EU, and the UK. The company is currently enrolling the UPBEAT Phase 1/2 multicenter clinical trial at sites in the U.S. and Canada, and has secured FDA IND acceptance, FDA Fast Track designation, EMA Orphan Drug designation, and Health Canada CTA approval for the program.

The company's core technology is the ART (Affinia Rationally-designed Therapies) platform, which combines AI, structural modeling, and next-generation sequencing to engineer novel AAV capsids, therapeutic payloads, and manufacturing processes. Two proprietary capsids anchor the platform: ATC-187, which delivers a fully human BAG3 transgene to cardiac tissue at 5-10-fold lower doses than conventional AAV9 or AAVrh74 capsids with homogeneous distribution across heart cells, and ATC-134, a blood-brain barrier penetrant capsid demonstrating greater than 90% neuron transduction in non-human primates. Affinia has also developed a proprietary high-yield manufacturing process achieving harvest titers above 6e15 vg/L, supporting potential commercial supply at 50-250L scale.

Affinia is a privately held, venture-backed company with no commercial revenue. It has raised approximately $210 million across a $60 million Series A (2020), $110 million Series B (2021, co-led by EcoR1 Capital and Farallon Capital), and $40 million Series C (October 2025, led by New Enterprise Associates with Eli Lilly & Company participation). The business model is clinical-stage gene therapy development oriented toward one-time treatment revenue; the lead asset is investigational and supplied at no cost to trial participants. Investors on the board include Atlas Venture, NEA, F-Prime Capital, and others, and management includes multiple former AveXis executives involved in the development and launch of Zolgensma.

Name

Affinia Therapeutics

Legal name

Affinia Therapeutics, Inc.

Website

https://affiniatx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Affinia Therapeutics is a clinical-stage biotech developing rationally designed AAV gene therapies for rare diseases, with lead program AFTX-201 in Phase 1/2 trials for BAG3-associated dilated cardiomyopathy and a broader platform spanning cardiac and CNS indications.

Ownership category

akta.pro rank

Product category

Gene Therapy / AAV Therapeutics

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• AAV gene therapy
• Gene therapy development
• Cardiac gene therapy
• Biologics manufacturing
• Rare disease therapeutics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Gene Therapy Development: Affinia Therapeutics is a clinical-stage biotech company developing gene therapies. No commercial revenue yet as the lead program AFTX-201 is in Phase 1/2 clinical trials. The company is funded through venture capital financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Affinia Therapeutics develops rationally designed AAV gene therapies targeting rare and prevalent diseases of the heart and central nervous system, with lead candidate AFTX-201 delivering a fully human BAG3 transgene via the proprietary ATC-187 capsid for BAG3-associated dilated cardiomyopathy. The company's ART platform combines AI, structural modeling, and next-generation sequencing to engineer novel capsids, payloads, and manufacturing processes that achieve superior tissue targeting at 5-10-fold lower doses than conventional AAV gene therapies.

Product overview

Affinia Therapeutics is a clinical-stage biotech company developing a pipeline of first-in-class and best-in-class AAV gene therapies. The core offering includes AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, which uses the proprietary ATC-187 capsid delivered via a one-time IV infusion. The company operates the ART (Affinia Rationally-designed Therapies) platform that employs AI and structural modeling to rationally design novel capsids (ATC-187 for cardiac, ATC-134 for CNS), payloads, and manufacturing processes. The platform enables lower dosing (5-10-fold) than conventional AAV gene therapies while achieving superior tissue transduction. Pipeline also includes programs for CNS diseases using BBB-penetrant capsids and collaborations for Myotonic Dystrophy Type 1.

Differentiator

Problem solved

Functional benefit

Products and services

• AFTX-201 Investigational AAV gene therapy delivering a fully human, full-length BAG3 transgene via the proprietary ATC-187 capsid, designed to address the underlying genetic cause of BAG3-associated dilated cardiomyopathy. Engineered for efficient cardiac transduction at doses 5-10-fold lower than conventional AAV gene therapies, administered as a one-time IV infusion.

Quantifiable outcome

• Doses 5-10-fold lower than conventional AAV gene therapies
• +4 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered minor, core and strategic.

• Houston Methodist HospitalminorOthers · 1 January 2026First planned clinical trial site for the UPBEAT clinical trial investigating AFTX-201 in BAG3 DCM patients.
• Forge BiologicscoreStrategic or Co-development PartnerForge Biologics serves as the GMP manufacturing partner for AFTX-201 production. The manufacturing process was successfully developed by Affinia and transferred to Forge for clinical supply manufacturing.
• Modalis TherapeuticsstrategicStrategic or Co-development PartnerJoint collaboration pairing Affinia's myotropic capsid ATC-187 with Modalis' epigenetic editing payload for development of a potential best-in-class gene therapy for Myotonic Dystrophy Type 1 (DM1).
• Montréal Heart InstituteminorOthersCanadian research institution with Dr. Rafik Tadros involved as a key opinion leader in BAG3 DCM research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiac diseases, including AAV-based therapies for genetic cardiomyopathies. Directly comparable as a cardiac-focused AAV gene therapy developer in similar stage and indication space as Affinia.
• Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV and lentiviral therapies for rare diseases, including cardiac and CNS indications. Comparable as a multi-platform rare disease gene therapy developer at similar clinical stage.
• Tenaya Therapeutics: Genetic medicines company developing AAV gene therapies and other modalities for cardiomyopathies and heart failure. Directly comparable as a cardiac-focused genetic medicine developer with gene therapy programs.
• Krystal Biotech: Commercial-stage gene therapy company with approved AAV-based therapy (VYJUVEK) for rare dermatological disease. Comparable as a clinical-to-commercial AAV gene therapy developer focused on rare monogenic diseases.
• uniQure: Clinical-stage AAV gene therapy company developing treatments for hemophilia, Huntington's disease, and other rare diseases. Comparable as an established AAV gene therapy developer at similar clinical stage.
• Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based therapies for CNS and rare diseases, led by former AveXis CEO Sean Nolan (now Affinia's Chairman). Comparable leadership pedigree and AAV gene therapy focus.
• Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Comparable as an AAV gene therapy developer for rare genetic diseases.

Broad incumbents

• REGENXBIO: Established AAV gene therapy platform company with approved therapy (ABECMA collab) and broad pipeline across ophthalmology, CNS, and metabolic diseases. Larger incumbent with comparable AAV platform technology and broader indication scope.
• BioMarin Pharmaceutical: Large rare disease biotech that developed and launched Roctavian, an AAV5 gene therapy for hemophilia A. Comparable as an established player commercializing AAV gene therapy for rare genetic diseases.
• Novartis (AveXis): Large pharmaceutical company that acquired AveXis for $8.7B and commercializes Zolgensma, the first systemic AAV gene therapy. Comparable as the established leader in AAV gene therapy commercialization and Affinia's lineage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/affinia-therapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affinia Therapeutics